124  0 Kommentare Galectin Therapeutics Investor Conference Call and Webinar Taking Place Today

The presentation can be accessed by dialing (844) 899-6544 and entering the conference ID: 3695038 or at the following webcast link: https://edge.media-server.com/mmc/p/hmudntyg. A copy of the presentation to be used for the call can be found on the Company’s website at https://investor.galectintherapeutics.com/investor-relations. The call is expected to last one hour, including a Q&A session that will follow the formal remarks.

Lesen Sie auch

Eli Lilly, SuperMicro und mehr

Die 10 überbewertesten Tech-Aktien im S&P 500

vor 1 Stunde

1 Kommentar

Vom Pharma-Thron gekickt

Bayer: Kursziel um knapp ein Drittel gesenkt

17.04.24, 12:51

Earnings Season

Dividendenerhöhung Nummer 62 – Johnson & Johnson mit Zahlen!

16.04.24, 15:58

Ihre wichtigsten Termine

Zahlen-Update von: LVMH, Johnson & Johnson, Bank of America und Morgan Stanley

16.04.24, 04:30

About Galectin Therapeutics
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin (formerly known as GR-MD-02) is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH-related fibrosis. This is the most common liver disease and one of the largest drug development opportunities available today. Additional development programs are in treatment of combination immunotherapy for advanced melanoma and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com.